Invokana 100 mg film-coated tablets
Authorisation EU/1/13/884/001-004 · Janssen-Cilag International NV
- Licence holder
- Janssen-Cilag International NV (all products →)
- Active substance
- Canagliflozin
- Clinical trials
- 10 clinical trials →
- Dosage form
- Film-coated tablet
- Route of administration
- Oral use
- ATC codes
- A10BK, A10BK02
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Canagliflozin: supply and approvals
4 authorised products on the HPRA list contain Canagliflozin. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 884. The HPRA list does not say whether it is on sale.
Other medicines with Canagliflozin in Ireland
5 other products on the HPRA list contain Canagliflozin, from 1 licence holder; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Invokana 300 mg film-coated tablets | Janssen-Cilag International NV | Centralised EU authorisation | Not stated |
| Vokanamet 150 mg/1000 mg Film-coated tablet | Janssen-Cilag International NV | Centralised EU authorisation | Not stated |
| Vokanamet 150 mg/850 mg Film-coated tablet | Janssen-Cilag International NV | Centralised EU authorisation | Not stated |
| Vokanamet 50 mg/1000 mg Film-coated tablet | Janssen-Cilag International NV | Centralised EU authorisation | Not stated |
| Vokanamet 50 mg/850 mg Film-coated tablet | Janssen-Cilag International NV | Centralised EU authorisation | Not stated |
Other substances in ATC group A10BK
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 4 other active substances share the group A10BK with this product:
Ertugliflozin l-pyroglutamic acid (2) · Dapagliflozin propanediol monohydrate equivalent to 10mg dapagliflozin (1) · Dapagliflozin propanediol monohydrate equivalent to 5mg dapagliflozin (1) · Empagliflozin (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Janssen-Cilag International NV holds 104 products on the HPRA list, with 44 different active substances; 2 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.